Skip to content

Hemogenyx (HEMO) Shares Surged 32.9% on New Antiviral Tech

Simon Mugo trader
Updated 9 Jan 2023

The Hemogenyx Pharmaceuticals PLC (LON: HEMO) share price surged 32.9% after revealing that it had made significant progress developing its Chimeric Bait Receptor (CBR) platform technology, which can be used to combat multiple deadly viruses.

new-recommended-broker-banner

YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


The company was initially focused on developing a cure for SARS-CoV-2 using its CBR platform but has since discovered that the technology can be used to treat other deadly viruses, such as Zika, Ebola, Dengue, Chikungunya and the Marburg virus.

Top Broker Recommendation

YOUR CAPITAL IS AT RISK. 68% OF RETAIL CFD ACCOUNTS LOSE MONEY

Investors cheered the announcement given the emerging threat posed by global pandemics, as evidenced by the COVID-19 pandemic that brought the entire economy to a standstill. Unlike the typical virus treatments based on antibodies, Hemogenyx’s CBR platform aims to develop a person’s “innate immunity.”

The Chimeric Bait Receptor (CBR) technology is used to program the immune cells responsible for developing “innate immunity”, such as macrophages and interferon using novel CBRs.

Hemogenyx has also developed a much simpler technology known as Bait-Macrophage Engagers (BMEs), which behave like antibodies and hunt virus particles in the blood and neutralise them.  

The company’s unique platforms are immune to the common problems associated with other technologies, such as virus mutations that render existing treatments ineffective over time. Both the CBR and BME platforms are insensitive to mutations. 

The two approaches operate using bait technology and will attack all viruses as long as they remain infectious. CBRs and BMEs are modular synthetic receptors and/or immune cell engagers that can be reconfigured rapidly to attack almost any virus. 

Hemogenyx’s new technologies also work on cancers and malignant cells; hence, they will help the company to continue developing its cancer therapies. The company also reiterated its commitment to expanding its cancer research, including progressing its CAR-T and CDX projects. 

CBRs and BMEs tend to boost the innate immunity of patients since they are assembled from parts of natural cellular receptors and/or engagers that power a person’s immune cells. Hence, they endow the host’s immune system with the ability to destroy invading pathogens.

Investors positive reaction to today’s announcement was justified, given that the new technologies could change how the world treats viruses.

*This is not investment advice. 

The Homogenyx share price. 

The Hemogenyx share price surged 32.97% to trade at 2.46p, from Friday’s closing price of 1.85p. 


YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading